Alpha-lipoic acid (ALA) is a potent antioxidant that functions in both water- and fat-soluble environments. In addition to its antioxidant activity, ALA plays a role in mitochondrial energy metabolism and helps muscle cells utilize glucose more efficiently, making it of interest in metabolic conditions such as insulin resistance and type 2 diabetes.

A substantial body of research supports the use of alpha-lipoic acid in peripheral neuropathy, particularly diabetic neuropathy. Multiple clinical trials and reviews have shown improvements in neuropathic symptoms—including pain, burning, numbness, and paresthesia—when ALA is administered, especially intravenously.

A randomized study published in European Review for Medical and Pharmacological Sciences (2009; 13[2]:133–139) evaluated 112 patients with moderate to severe carpal tunnel syndrome. Participants were assigned to receive either:

  • Alpha-lipoic acid (600 mg/day) plus gamma-linolenic acid (360 mg/day), or

  • A B-vitamin combination (vitamins B6, B12, and thiamin)

After 90 days, the group receiving alpha-lipoic acid and gamma-linolenic acid experienced greater reductions in symptoms and improved functional outcomes compared to the B-vitamin group.

Further support comes from a meta-analysis published in Diabetic Medicine (2004; 21[2]:114–121), which found that 300 mg of intravenous alpha-lipoic acid daily for three weeks significantly reduced neuropathy symptoms in patients with diabetes.

Additional confirmation was reported in the Netherlands Journal of Medicine (2010 Apr; 68[4]:158–162). This study found that intravenous alpha-lipoic acid improved neuropathic symptoms and that oral supplementation at 600 mg per day also produced clinically meaningful benefits, though IV administration showed more consistent effects.

Why this still matters

  • Neuropathy remains a common, difficult-to-treat complication of diabetes

  • Alpha-lipoic acid addresses oxidative stress and mitochondrial dysfunction, not just symptoms

  • Both IV and oral forms show benefit, with IV therapy producing more robust short-term results